Analysts Are Bullish on Top Healthcare Stocks: HTG Molecular Diagnostics (HTGM), Sarepta Therapeutics (SRPT)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HTG Molecular Diagnostics (HTGM) and Sarepta Therapeutics (SRPT) with bullish sentiments.

HTG Molecular Diagnostics (HTGM)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on HTG Molecular Diagnostics today and set a price target of $8. The company’s shares closed yesterday at $2.61, close to its 52-week low of $2.03.

Selvaraju commented:

“As we roll forward the DCF analysis, our estimated market value of the firm has increased to $231M from $222M. This includes an asset value at $241M for the HTG EdgeSeq platform, with a 15% discount rate and 0% terminal growth rate, excluding $10M debt and assuming 28.7M shares outstanding at the end of 1Q20.”

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.6% and a 32.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on HTG Molecular Diagnostics is a Moderate Buy with an average price target of $7, which is a 168.2% upside from current levels. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $6 price target.

See today’s analyst top recommended stocks >>

Sarepta Therapeutics (SRPT)

In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Sarepta Therapeutics, with a price target of $267. The company’s shares closed yesterday at $133.93.

Chattopadhyay commented:

“Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.75, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.9%, and tax rate of 15% beginning in FY 2024.”

According to TipRanks.com, Chattopadhyay is a 2-star analyst with an average return of 0.4% and a 46.3% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.

Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $207.06, implying a 54.6% upside from current levels. In a report issued on February 22, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $217 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts